MUSK and myasthenia gravis: In fact, MycarinG sub-group analysis suggested MuSK patients had a higher reduction in MG-ADL (reduction of four to seven points, compared to around three points, in the different dosing groups) scores compared to their AChR counterparts (derived from a total of 13 MuSK- and 120 AChR-MG patients receiving active treatment) [47].